BR0116757A - Método para o tratamento de infecções pulmonares causadas por bactérias gram-negativas e composição para inalação farmaceuticalmente aceitável. - Google Patents

Método para o tratamento de infecções pulmonares causadas por bactérias gram-negativas e composição para inalação farmaceuticalmente aceitável.

Info

Publication number
BR0116757A
BR0116757A BR0116757-0A BR0116757A BR0116757A BR 0116757 A BR0116757 A BR 0116757A BR 0116757 A BR0116757 A BR 0116757A BR 0116757 A BR0116757 A BR 0116757A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
gram
infections caused
negative bacteria
treatment
Prior art date
Application number
BR0116757-0A
Other languages
English (en)
Other versions
BRPI0116757B8 (pt
BR0116757B1 (pt
Inventor
Alan Bruce Montgomery
Original Assignee
Salus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0116757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salus Pharma Inc filed Critical Salus Pharma Inc
Publication of BR0116757A publication Critical patent/BR0116757A/pt
Publication of BR0116757B1 publication Critical patent/BR0116757B1/pt
Publication of BRPI0116757B8 publication Critical patent/BRPI0116757B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"MéTODO PARA O TRATAMENTO DE INFECçõES PULMONARES CAUSADAS POR BACTéRIAS GRAM-NEGATIVAS E COMPOSIçãO PARA INALAçãO FARMACEUTICAMENTE ACEITáVEL". A presente invenção refere-se a um método e a uma composição para o tratamento de infecções pulmonares causadas por bactérias gram-negativas adequado para o tratamento de infecções causadas como Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species e Serratia marcescens, bem como aquelas causadas por Burkholdería cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans e Pseudomonas aeruginosa resistente a múltiplas drogas através da utilização de uma formulação concentrada de aztreonam, ou um sal farmaceuticamente aceitável do mesmo, ministrado como um aerossol ou uma formulação de pó seco.
BRPI0116757A 2000-12-27 2001-12-20 composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória BRPI0116757B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
US60/258,423 2000-12-27
PCT/US2001/050062 WO2002051356A2 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (3)

Publication Number Publication Date
BR0116757A true BR0116757A (pt) 2003-11-04
BR0116757B1 BR0116757B1 (pt) 2014-02-04
BRPI0116757B8 BRPI0116757B8 (pt) 2021-05-25

Family

ID=22980480

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0116757A BRPI0116757B8 (pt) 2000-12-27 2001-12-20 composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória

Country Status (19)

Country Link
US (6) US6660249B2 (pt)
EP (2) EP1353647B1 (pt)
JP (1) JP4646489B2 (pt)
AT (1) ATE502623T1 (pt)
AU (1) AU2002231244B2 (pt)
BE (1) BE2011C029I2 (pt)
BR (1) BRPI0116757B8 (pt)
CA (2) CA2708703C (pt)
CY (2) CY1111571T1 (pt)
DE (2) DE122011100043I1 (pt)
DK (2) DK1353647T3 (pt)
ES (2) ES2406405T3 (pt)
FR (1) FR11C0030I2 (pt)
IL (3) IL156596A0 (pt)
LU (1) LU91851I2 (pt)
NL (1) NL300492I2 (pt)
NO (3) NO329643B1 (pt)
PT (2) PT2301524E (pt)
WO (1) WO2002051356A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
DE122011100043I1 (de) * 2000-12-27 2011-12-15 Gilead Sciences Inc Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
WO2003075890A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CN1681812A (zh) 2002-08-05 2005-10-12 特瓦药厂有限公司 氨曲南的制备
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AU2004231342A1 (en) * 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
EP1622900A1 (en) 2003-05-15 2006-02-08 Teva Gyogyszergyar Reszvenytarsasag Aztreonam beta-polymorph with very low residual solvent content
WO2004103478A1 (en) * 2003-05-20 2004-12-02 Collins James F Ophthalmic drug delivery system
US7262293B2 (en) * 2003-07-02 2007-08-28 Corus Pharma Aztreonam L-lysine and methods for the preparation thereof
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
PT1888576E (pt) 2005-05-09 2009-04-03 Sicor Inc Processo de produção de aztreonam
WO2008039987A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Methods of treating pulmonary distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
BRPI0817636A2 (pt) * 2007-10-01 2019-09-24 Gilead Sciences Inc aztreonam lisina inalada para o tratamento de déficits na qualidade de vida relacionada à saúde em doenças pulmonares
EP2268142B1 (en) 2007-11-27 2017-02-22 Algipharma As Use of alginated oligomers in combating biofilms
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
CN102458474B (zh) 2009-06-03 2014-06-11 阿尔吉法玛公司 使用藻酸盐低聚物和抗生素治疗不动杆菌
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
WO2013109217A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Pharmaceutical formulations comprising aztreonam
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
WO2014158201A1 (en) * 2013-03-28 2014-10-02 Pharmacaribe, Llc Compositions, formulations and methods of bio-balancing the ph of sterile isotonic saline and hypertonic saline solutions
EP2981247B1 (en) 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
CN109475709B (zh) 2016-05-03 2022-12-27 精呼吸股份有限公司 使用液滴输送装置生成液滴并将其输送到肺部系统的方法
US11529476B2 (en) 2017-05-19 2022-12-20 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
KR20240034855A (ko) 2017-06-10 2024-03-14 아이노비아 인코포레이티드 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 방법들 및 디바이스들
JP2020536614A (ja) 2017-10-04 2020-12-17 ニューマ・リスパイラトリー・インコーポレイテッド 呼吸により電気的に作動するインライン液滴送達装置および使用方法
WO2019079461A1 (en) 2017-10-17 2019-04-25 Pneuma Respiratory, Inc. NASAL MEDICATION DELIVERY APPARATUS AND METHODS OF USE
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法
CN111647537B (zh) * 2020-06-18 2022-04-26 浙江工业大学 一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
WO2022271848A1 (en) 2021-06-22 2022-12-29 Pneuma Respiratory, Inc. Droplet delivery device with push ejection

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572801A (en) * 1896-12-08 Telephone-exchange
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US9126A (en) * 1852-07-13 Marcus r
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
DK0754050T3 (da) * 1994-01-14 2002-10-21 Xoma Technology Ltd Anti-gram-positive bakterielle fremgangsmåder og materialer
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
WO1998009990A1 (fr) 1996-09-04 1998-03-12 Takara Shuzo Co., Ltd. Antigenes fongiques et processus de fabrication
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
BR9916296A (pt) * 1998-12-17 2004-06-29 Pathogenesis Corp Método para tratamento de bronquite crÈnica severa (bronquiectase) com um antibiótico em forma de aerossol
IL146842A0 (en) 1999-06-01 2002-07-25 Biogen Inc Polymer conjugates of hedgehog proteins and uses
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
DK1223915T3 (da) * 1999-10-29 2006-03-06 Nektar Therapeutics Törpulverpræparater med forbedret dispersivitet
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE122011100043I1 (de) 2000-12-27 2011-12-15 Gilead Sciences Inc Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
WO2003031163A2 (en) * 2001-10-08 2003-04-17 California Institute Of Technology Microfabricated lenses, methods of manufacture thereof, and applications therefor
US20040247628A1 (en) 2001-10-24 2004-12-09 Frank-Christophe Lintz Kit for the preparation of a pharmaceutical composition
WO2003075890A1 (en) 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
WO2004052333A1 (en) 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US7262293B2 (en) 2003-07-02 2007-08-28 Corus Pharma Aztreonam L-lysine and methods for the preparation thereof
BRPI0817636A2 (pt) 2007-10-01 2019-09-24 Gilead Sciences Inc aztreonam lisina inalada para o tratamento de déficits na qualidade de vida relacionada à saúde em doenças pulmonares

Also Published As

Publication number Publication date
NL300492I2 (nl) 2017-11-02
EP1353647B1 (en) 2011-03-23
BRPI0116757B8 (pt) 2021-05-25
US20080050439A1 (en) 2008-02-28
FR11C0030I1 (pt) 2011-09-23
IL221036A0 (en) 2012-08-30
ES2406405T3 (es) 2013-06-06
ES2360692T3 (es) 2011-06-08
NO2011001I1 (no) 2011-02-07
CY1111571T1 (el) 2014-04-09
US9533000B2 (en) 2017-01-03
IL156596A (en) 2012-07-31
DK2301524T3 (da) 2013-07-15
US7208141B2 (en) 2007-04-24
CY2011012I1 (el) 2014-04-09
BE2011C029I2 (pt) 2021-07-26
IL156596A0 (en) 2004-01-04
US20120093890A1 (en) 2012-04-19
DE122011100043I1 (de) 2011-12-15
CY2011012I2 (el) 2014-04-09
DE60144291D1 (de) 2011-05-05
JP4646489B2 (ja) 2011-03-09
EP1353647A4 (en) 2007-05-09
CA2708703A1 (en) 2002-07-04
EP2301524A1 (en) 2011-03-30
US20170296517A1 (en) 2017-10-19
LU91851I9 (pt) 2019-01-03
CA2433280A1 (en) 2002-07-04
NO20032946L (no) 2003-08-26
PT2301524E (pt) 2013-07-10
CA2433280C (en) 2010-09-21
NO329643B1 (no) 2010-11-22
AU2002231244B2 (en) 2006-06-29
WO2002051356A2 (en) 2002-07-04
JP2004516302A (ja) 2004-06-03
PT1353647E (pt) 2011-05-24
US20140037735A1 (en) 2014-02-06
EP2301524B1 (en) 2013-04-24
US20030055034A1 (en) 2003-03-20
US20050129623A1 (en) 2005-06-16
LU91851I2 (fr) 2011-10-03
US6660249B2 (en) 2003-12-09
FR11C0030I2 (fr) 2012-03-16
NO2011001I2 (no) 2013-05-27
NO20101377L (no) 2003-08-26
WO2002051356A3 (en) 2002-10-31
DK1353647T3 (da) 2011-06-14
ATE502623T1 (de) 2011-04-15
BR0116757B1 (pt) 2014-02-04
CA2708703C (en) 2012-12-04
EP1353647A2 (en) 2003-10-22
NO20032946D0 (no) 2003-06-26

Similar Documents

Publication Publication Date Title
BR0116757A (pt) Método para o tratamento de infecções pulmonares causadas por bactérias gram-negativas e composição para inalação farmaceuticalmente aceitável.
CY1114621T1 (el) Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
JP4745340B2 (ja) 細菌性呼吸器感染症を治療するためのエーロゾル化されたホスホマイシン／アミノグリコシド組合せ
Tsuchiya et al. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities
WO2011005354A3 (en) Gallium formulation for the treatment and prevention of infectious diseases
EP2594272A3 (en) Aerosolized fluoroquinolones and uses thereof
HK1068784A1 (en) Optimised formulation of tobrarmycin for aerosolization
EP3268010A1 (en) Compositions and methods for treating bacterial infection
Lorenz et al. Efficacy and tolerability of 5-vs 10-day cefixime therapy in acute exacerbations of chronic bronchitis
AR040420A1 (es) Aztreonam inhalable para el tratamiento y la prevencion de infecciones bacterianas pulmonares
WO2006125123A3 (en) Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
CY1114144T1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales
Aswapokee et al. In vitro activity of cefixime: A new orally active cephalosporin
Rothstein et al. P-113d, an Antimicrobial Peptide Active
AU2014201794A1 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: SALUS PHARMA, INC. (US)

Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO DE TRANSFERENCIA NO 004866/SP DE 18/03/2005, QUEIRA APRESENTAR DOCUMENTO DE CESSAO ONDE CONSTE O NUMERO DO PEDIDO BRASILEIRO A SER TRANSFERIDO, ASSINADO PELA CEDENTE, CESSIONARIA E DUAS TESTEMUNHAS, COM AS DEVIDAS ASSINATURAS NOTARIZADAS E COM A RESPECTIVA LEGALIZACAO CONSULAR.

B25B Requested transfer of rights rejected

Owner name: SALUS PHARMA, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA DE TITULAR SOLICITADO ATRAVES DA PETICAO NO 004866/SP DE 18/03/2005, POR NAO CUMPRIMENTO DE EXIGENCIA PUBLICADA NA RPI 1865 DE 03/10/2006.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: CORUS PHARMA, INC. (US)

Free format text: TRANSFERIDO POR FUSAO DE: SALUS PHARMA, INC.

B25A Requested transfer of rights approved

Owner name: GILEAD SCIENCES, INC. (US)

Free format text: TRANSFERIDO POR FUSAO DE: CORUS PHARMA, INC.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NA PETICAO INPI/DESP NO 018110035272 DE 12/09/2011

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 20/12/2021